NYSE$CRL
Charles River Laboratories International Inc · Q4 2024 earnings
Q4 2024 earnings · · Before market open · Investor relations
Briefing
Charles River Labs reported a revenue decline and a GAAP net loss in Q4 2024 due to goodwill impairment but saw adjusted earnings growth.
Charles River Labs reported Q4 2024 revenue of $1.00 billion, a 1.1% YoY decline, primarily due to weak performance in the DSA and RMS segments. The company posted a GAAP net loss of $215.7 million, largely driven by a $215 million goodwill impairment in the Biologics Solutions unit. However, non-GAAP earnings per share increased by 8.1% YoY, supported by cost reductions and higher Manufacturing segment revenue.
- GAAP net loss of $215.7 million due to a $215 million goodwill impairment.
- Revenue declined 1.1% YoY to $1.00 billion, with organic revenue down 1.8%.
- Non-GAAP EPS rose 8.1% YoY to $2.66, driven by cost savings and higher Manufacturing revenue.
- Manufacturing segment grew 1.6%, while DSA revenue declined 3.6% due to lower demand.
Headline financials
Revenue & EPS history
Charles River Labs · Revenue · Quarterly
$1B
Revenue by segment
Charles River Labs · $1.03B total across 3 segments · Q3 2023
- Discovery & Safety Assessment$664M+7.2%64.7%
- Research Models & Services$187M+3.7%18.2%
- Manufacturing Solutions$176M-7.3%17.1%
Forward guidance
Charles River expects stable biopharmaceutical demand but anticipates revenue pressure due to lower DSA pricing and weaker CDMO performance.
Tailwinds
- Cost savings initiatives expected to improve profitability.
- Manufacturing segment remains a key growth driver.
- Stable to slightly improved demand from small and mid-sized biotech clients.
- Company plans to repurchase approximately $350 million in stock.
- Non-GAAP EPS guidance of $9.10 - $9.60 for FY 2025.
Headwinds
- Continued budget constraints from large biopharmaceutical clients.
- DSA segment expected to face pricing headwinds.
- CDMO business to experience lower commercial revenue.
- Organic revenue expected to decline 3.5% - 5.5% YoY.
- GAAP EPS guidance of $4.30 - $4.80 reflects ongoing revenue pressures.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
+0.1%
Avg return
Earnings day
+0.5%
Avg return
5 days after
+0.7%
Avg return
30 days after
47%
32 / 68 earnings
Positive
+18.4%
Q1 2025
Best reaction
-13.3%
Q3 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.8% | -9.0% | -0.1% | |
| Q4 2025 | -1.8% | +3.1% | -3.1% | |
| Q3 2025 | -5.5% | -5.0% | +3.6% | |
| Q1 2025 | +18.4% | +24.0% | +25.4% | |
| Q4 2024 | +6.9% | +10.4% | +8.3% | |
| Q3 2024 | +11.5% | +17.0% | +1.7% | |
| Q2 2024 | -11.7% | -15.1% | -17.8% | |
| Q1 2024 | -3.0% | -1.0% | -8.7% | |
| Q4 2023 | +11.4% | +11.2% | +17.6% | |
| Q3 2023 | -7.3% | -7.0% | +11.8% | |
| Q2 2023 | +5.5% | +5.2% | -3.2% | |
| Q1 2023 | +2.7% | +1.0% | +6.1% | |
| Q4 2022 | -6.7% | -9.0% | -20.4% | |
| Q3 2022 | +4.8% | +9.0% | +7.4% | |
| Q2 2022 | -6.6% | -9.4% | -17.8% | |
| Q1 2022 | -1.2% | -8.9% | -3.3% | |
| Q4 2021 | -6.7% | -6.1% | -8.3% | |
| Q3 2021 | -12.2% | -13.4% | -17.3% | |
| Q2 2021 | -0.3% | -0.4% | +9.3% | |
| Q1 2021 | +4.0% | +3.2% | -0.1% | |
| Q4 2020 | +2.0% | -1.1% | -0.0% | |
| Q3 2020 | +2.6% | +7.0% | +3.7% | |
| Q2 2020 | +6.8% | +7.3% | +0.4% | |
| Q1 2020 | +11.1% | +12.0% | +24.2% | |
| Q4 2019 | +8.6% | +11.9% | -21.3% | |
| Q3 2019 | -2.5% | +1.1% | +12.0% | |
| Q2 2019 | -5.1% | -10.3% | -7.0% | |
| Q1 2019 | -4.2% | -4.1% | -10.4% | |
| Q4 2018 | +8.1% | +9.0% | +11.1% | |
| Q3 2018 | +8.8% | +6.8% | +3.0% | |
| Q2 2018 | -5.2% | -6.6% | -1.6% | |
| Q1 2018 | +0.3% | -1.0% | +8.5% | |
| Q4 2017 | +8.2% | +6.0% | +9.9% | |
| Q3 2017 | -13.3% | -14.3% | -11.9% | |
| Q2 2017 | -1.7% | -0.2% | +10.0% | |
| Q1 2017 | -3.8% | -2.3% | +2.8% | |
| Q4 2016 | +7.6% | +7.3% | +8.4% | |
| Q3 2016 | -9.0% | -5.1% | -3.0% | |
| Q2 2016 | -0.0% | -3.1% | -3.0% | |
| Q1 2016 | +2.5% | — | — | |
| Q4 2015 | +3.9% | — | — | |
| Q3 2015 | +5.7% | — | — | |
| Q2 2015 | +1.4% | — | — | |
| Q1 2015 | -8.8% | — | — | |
| Q4 2014 | +6.3% | — | — | |
| Q3 2014 | -1.9% | — | — | |
| Q2 2014 | +6.0% | — | — | |
| Q1 2014 | -6.6% | — | — | |
| Q4 2013 | -1.6% | — | — | |
| Q3 2013 | -1.2% | — | — | |
| Q2 2013 | +3.4% | — | — | |
| Q1 2013 | -3.9% | — | — | |
| Q4 2012 | +0.9% | — | — | |
| Q3 2012 | -5.3% | — | — | |
| Q2 2012 | +2.3% | — | — | |
| Q1 2012 | +1.8% | — | — | |
| Q4 2010 | -1.3% | — | — | |
| Q4 2011 | -1.3% | — | — | |
| Q3 2011 | -5.0% | — | — | |
| Q2 2011 | -9.4% | — | — | |
| Q1 2010 | -2.4% | — | — | |
| Q1 2011 | -0.1% | — | — | |
| Q4 2008 | -0.9% | — | — | |
| Q3 2010 | -4.4% | — | — | |
| Q3 2009 | -4.4% | — | — | |
| Q2 2010 | +3.6% | — | — | |
| Q4 2009 | +3.6% | — | — | |
| Q2 2009 | +3.6% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro